MoonLake Immunotherapeutics

11 days ago · benzinga.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) stock is trading higher on Thursday with a session volume of 4.20 million compared to the average volume of 1.494 million, according to Benzinga Pro data.

2 months ago · seekingalpha.com

MoonLake Immunotherapeutics offers a compelling investment case despite sonelokimab's mixed clinical results, focusing on regulatory progress and commercial viability. MLTX can file for HS approval without another major trial, accelerating potential revenue and reducing dilution risk, with cash runway projected through mid-2028. Sonelokimab's durability and differentiated nanobody structure support its commercial potential, but competitive execution and access will be key to market success.

3 months ago · reuters.com

MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage trial involving ​adults with an inflammatory disease who had not previously ‌received biologic medicines.

3 months ago · globenewswire.com

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritis Meaningful and statistically significant improvements were seen across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCS Blinded safety analysis suggests a profile consistent with previous studies and no new safety signals were identified, reinforcing sonelokimab's potential to become a leading treatment option for patients living with psoriatic arthritis, and enabling MoonLake's entry into another multi-billion dollar indication The IZAR-1 trial remains blinded and will continue until Week 52 with MoonLake expecting the full readout in H1 2027 whereas the IZAR-2 trial (a trial in TNF-refractory patients) is expected to complete enrollment in Q3 2026 MoonLake ended the second quarter with $ 537.0 million in cash, cash equivalents and short-term marketable debt securities and expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its debt facility with Hercules Capital ZUG, Switzerland, August 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis (PsA) and reported second quarter 2026 financial results. IZAR-1 Phase 3 trial Week 16 positive topline results The IZAR Phase 3 program consists of two registrational global randomized, double-blind trials, IZAR-1 and IZAR-2, designed to evaluate the efficacy and safety of sonelokimab in adults with active psoriatic arthritis (PsA).

3 months ago · zacks.com

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

4 months ago · fool.com

This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.

4 months ago · seekingalpha.com

MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and strong long-term data for sonelokimab in hidradenitis suppurativa [HS]. MLTX expects to submit a BLA for sonelokimab in HS by end of September 2026, targeting both adults and adolescents, with possible acceptance for review by November 2026. 52-week VELA data show 67.2% HiSCR75 response, positioning sonelokimab as a potential best-in-class therapy and supporting a broad label proposal thanks to VELA-TEEN adolescent study.

4 months ago · fool.com

It aims to raise up to $200 million in the offering. This will support its efforts to bring its top drug candidate to market.

4 months ago · globenewswire.com

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of $20.00 and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase up to 1,000,000 Class A ordinary shares at a public offering price per pre-funded warrant of $19.9999, which equals the public offering price per Class A ordinary share less the $0.0001 per share exercise price of each pre-funded warrant. The pre-funded warrants are exercisable immediately. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses payable by MoonLake, are expected to be approximately $200 million. In addition, MoonLake has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,500,000 Class A ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 25, 2026 subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by MoonLake.

4 months ago · seekingalpha.com

MoonLake Immunotherapeutics is positioned for upside on differentiated efficacy and a large, underpenetrated hidradenitis suppurativa, or HS, market. Recent Phase 3 VELA data show sonelokimab achieves superior HiSCR75/100 response rates and meaningful patient-reported quality of life improvements. The commercial strategy targets a best-in-class FDA label by emphasizing efficacy, safety, and patient outcomes, supporting share gains in a $10–15B market.